KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Common Equity (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Common Equity for 16 consecutive years, with $76.6 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 21.35% to $76.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $76.6 million through Dec 2025, down 21.35% year-over-year, with the annual reading at $76.6 million for FY2025, 21.35% down from the prior year.
  • Common Equity hit $76.6 million in Q4 2025 for Arbutus Biopharma, down from $77.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $169.4 million in Q4 2021 to a low of $76.6 million in Q4 2025.
  • Historically, Common Equity has averaged $118.9 million across 5 years, with a median of $117.0 million in 2023.
  • Biggest five-year swings in Common Equity: skyrocketed 66.17% in 2021 and later crashed 32.24% in 2025.
  • Year by year, Common Equity stood at $169.4 million in 2021, then decreased by 19.23% to $136.9 million in 2022, then fell by 22.53% to $106.0 million in 2023, then decreased by 8.16% to $97.4 million in 2024, then decreased by 21.35% to $76.6 million in 2025.
  • Business Quant data shows Common Equity for ABUS at $76.6 million in Q4 2025, $77.4 million in Q3 2025, and $83.0 million in Q2 2025.